These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 36785962)
21. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844 [TBL] [Abstract][Full Text] [Related]
22. Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in Batchala PP; Muttikkal TJE; Donahue JH; Patrie JT; Schiff D; Fadul CE; Mrachek EK; Lopes MB; Jain R; Patel SH AJNR Am J Neuroradiol; 2019 Mar; 40(3):426-432. PubMed ID: 30705071 [TBL] [Abstract][Full Text] [Related]
23. Loss of BCAT1 Expression is a Sensitive Marker for IDH-Mutant Diffuse Glioma. Chen YY; Ho HL; Lin SC; Hsu CY; Ho DM Neurosurgery; 2019 Sep; 85(3):335-342. PubMed ID: 30113684 [TBL] [Abstract][Full Text] [Related]
24. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Labussière M; Idbaih A; Wang XW; Marie Y; Boisselier B; Falet C; Paris S; Laffaire J; Carpentier C; Crinière E; Ducray F; El Hallani S; Mokhtari K; Hoang-Xuan K; Delattre JY; Sanson M Neurology; 2010 Jun; 74(23):1886-90. PubMed ID: 20427748 [TBL] [Abstract][Full Text] [Related]
25. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas. Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590 [TBL] [Abstract][Full Text] [Related]
26. Surgically treated incidentally discovered low-grade gliomas are mostly IDH mutated and 1p19q co-deleted with favorable prognosis. Zhang ZY; Chan AK; Ng HK; Ding XJ; Li YX; Shi ZF; Zhu W; Zhong P; Wang Y; Mao Y; Yao Y; Zhou LF Int J Clin Exp Pathol; 2014; 7(12):8627-36. PubMed ID: 25674227 [TBL] [Abstract][Full Text] [Related]
27. Diffuse glioma - Rare homozygous IDH point mutation, is it an oncogenetic mechanism? Singh A; Gurav M; Dhanavade S; Shetty O; Epari S Neuropathology; 2017 Dec; 37(6):582-585. PubMed ID: 28782849 [TBL] [Abstract][Full Text] [Related]
28. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation. Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234 [TBL] [Abstract][Full Text] [Related]
29. Analysis of isocitrate dehydrogenase 1 mutation in 97 patients with glioma. Zhou YX; Wang JX; Feng M; Sun CM; Sun T; Chen GL; Du ZW J Mol Neurosci; 2012 Jul; 47(3):442-7. PubMed ID: 22113362 [TBL] [Abstract][Full Text] [Related]
30. Morphologically, genetically and spatially mixed astrocytoma and oligodendroglioma; chronological acquisition of 1p/19q codeletion and CDKN2A deletion: a case report. Takami H; Mukasa A; Takayanagi S; Koike T; Matsuura R; Ikemura M; Ushiku T; Yoshikawa G; Shibahara J; Tanaka S; Saito N Brain Tumor Pathol; 2023 Jan; 40(1):26-34. PubMed ID: 36572828 [TBL] [Abstract][Full Text] [Related]
31. [Precision Medicine for IDH-mutant Diffuse Glioma(Lower-grade Glioma)]. Mukasa A No Shinkei Geka; 2022 Jan; 50(1):8-18. PubMed ID: 35169082 [TBL] [Abstract][Full Text] [Related]
32. Clinical implications of molecular analysis in diffuse glioma stratification. Mizoguchi M; Hata N; Kuga D; Hatae R; Akagi Y; Sangatsuda Y; Fujioka Y; Takigawa K; Funakoshi Y; Suzuki SO; Iwaki T Brain Tumor Pathol; 2021 Jul; 38(3):210-217. PubMed ID: 34268651 [TBL] [Abstract][Full Text] [Related]
33. [Prognostic significance of combined TERT and IDH gene mutation analysis in diffusely infiltrating gliomas]. Liu QQ; Yin XX; Zou Y; Yu TP; Gong J; Chen XQ; Nie L; Xu M; Zhang MN; Zhou Q; Chen N Zhonghua Bing Li Xue Za Zhi; 2018 Sep; 47(9):658-663. PubMed ID: 30220117 [No Abstract] [Full Text] [Related]
34. H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology. Ammendola S; Caldonazzi N; Simbolo M; Piredda ML; Brunelli M; Poliani PL; Pinna G; Sala F; Ghimenton C; Scarpa A; Barresi V Virchows Arch; 2021 Nov; 479(5):987-996. PubMed ID: 34165590 [TBL] [Abstract][Full Text] [Related]
35. Infrequent RAS mutation is not associated with specific histological phenotype in gliomas. Makino Y; Arakawa Y; Yoshioka E; Shofuda T; Minamiguchi S; Kawauchi T; Tanji M; Kanematsu D; Nonaka M; Okita Y; Kodama Y; Mano M; Hirose T; Mineharu Y; Miyamoto S; Kanemura Y BMC Cancer; 2021 Sep; 21(1):1025. PubMed ID: 34525976 [TBL] [Abstract][Full Text] [Related]
36. Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis. Richardson TE; Snuderl M; Serrano J; Karajannis MA; Heguy A; Oliver D; Raisanen JM; Maher EA; Pan E; Barnett S; Cai C; Habib AA; Bachoo RM; Hatanpaa KJ J Neurooncol; 2017 May; 133(1):183-192. PubMed ID: 28421459 [TBL] [Abstract][Full Text] [Related]
37. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status. Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492 [TBL] [Abstract][Full Text] [Related]
38. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion. Chen SC; Lo CM; Wang SH; Su EC BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275 [TBL] [Abstract][Full Text] [Related]
39. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign. Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467 [TBL] [Abstract][Full Text] [Related]